Related Experiment Video
Updated: Jul 9, 2026

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
Published on: September 1, 2015
Vasopressin directly regulates cyst growth in polycystic kidney disease
Xiaofang Wang1, Yanhong Wu, Christopher J Ward
1Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Abstract:
The polycystic kidney diseases (PKD) are a group of genetic disorders causing renal failure and death from infancy to adulthood. Arginine vasopressin (AVP) V2 receptor antagonists inhibit cystogenesis in animal models of cystic kidney diseases, presumably by downregulating cAMP signaling, cell proliferation, and chloride-driven fluid secretion. For confirmation that the protective effect of these drugs is due to antagonism of AVP, PCK (Pkhd1(-/-)) and Brattleboro (AVP(-/-)) rats were crossed to generate rats with PKD and varying amounts of AVP. At 10 and 20 weeks of age, PCK AVP(-/-) rats had lower renal cAMP and almost complete inhibition of cystogenesis compared with PCK AVP(+/+) and PCK AVP(+/-) rats. The V2 receptor agonist 1-deamino-8-d-arginine vasopressin increased renal cAMP and recovered the full cystic phenotype of PCK AVP(-/-) rats and aggravated the cystic disease of PCK AVP(+/+) rats but did not induce cystic changes in wild-type rats. These observations indicate that AVP is a powerful modulator of cystogenesis and provide further support for clinical trials of V2 receptor antagonists in PKD.
Insights
Arginine vasopressin (AVP) drives cyst growth in polycystic kidney disease (PKD). Blocking the AVP V2 receptor inhibits cystogenesis, suggesting V2 receptor antagonists are promising for PKD treatment.
Area of Science:
- Nephrology
- Genetics
- Pharmacology
Background:
- Polycystic kidney diseases (PKD) are genetic disorders leading to kidney failure.
- Arginine vasopressin (AVP) V2 receptor antagonists show potential in animal models by reducing cyst growth.
- The precise role of AVP in PKD cystogenesis requires further elucidation.
Purpose of the Study:
- To confirm the protective effect of AVP V2 receptor antagonists is due to AVP antagonism.
- To investigate the role of AVP in modulating cystogenesis in PKD models.
- To provide evidence supporting clinical trials of V2 receptor antagonists for PKD.
Main Methods:
- Generation of PCK (Pkhd1(-/-)) and Brattleboro (AVP(-/-)) rat crosses to create rats with PKD and varying AVP levels.
- Measurement of renal cyclic adenosine monophosphate (cAMP) levels at 10 and 20 weeks.
- Administration of a V2 receptor agonist to assess its impact on cystogenesis and renal cAMP.
Main Results:
- PCK AVP(-/-) rats exhibited significantly lower renal cAMP and inhibited cystogenesis compared to PCK AVP(+/+) and PCK AVP(+/-) rats.
- The V2 receptor agonist increased renal cAMP and exacerbated cystogenesis in PCK rats, while not affecting wild-type rats.
- These findings demonstrate AVP as a key modulator of cystogenesis in PKD.
Conclusions:
- AVP is a critical factor in the development and progression of polycystic kidney disease.
- Inhibition of AVP signaling via V2 receptor antagonism effectively suppresses cystogenesis.
- These results strongly support the clinical investigation of V2 receptor antagonists for treating PKD.
Related Concept Videos
Physiology of the Genitourinary System II: Tubular Reabsorption and Secretion
Hormonal Regulation
Renal Tubule and Collecting Duct
Proximal Convoluted Tubule (PCT):
The PCT is the initial segment of the renal tubule, extending from the Bowman's capsule that encloses the glomerulus. Its convoluted structure and microvilli-lined cells increase the surface area for reabsorption. The PCT reabsorbs glucose, amino acids, sodium, and water from the filtrate, ensuring essential...
Physiology of the Genitourinary System III: Urine Concentration and Dilution
Nephrons
Diabetes Insipidus II: Pathophysiology

